1.            Lerer, E. et al. Effects of psilocybin, psychedelic mushroom extract and 5-hydroxytryptophan on brain immediate early gene expression: Interaction with serotonergic receptor modulators. Front. Pharmacol. 15, (2024).

2.            Shahar, O. et al. Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain. Mol. Psychiatry (2024) doi:10.1038/s41380-024-02477-w.

3.            Heresco-Levy, U. & Lerer, B. Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders. Mol. Psychiatry 29, 146–152 (2024).

4.            Singh, S. et al. Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder. Transl. Psychiatry 13, (2023).

5.            Moskovich, D. et al. Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011)). Cancer Lett. 563, (2023).

6.            Moskovich, D. et al. Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment (Oncogene, (2021), 40, 44, (6248-6257), 10.1038/s41388-021-02020-z). Oncogene 42, 1508 (2023).

7.            Wolf, G. et al. Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Mol. Psychiatry 28, 44–58 (2023).

8.            Shahar, O. et al. Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications. Int. J. Mol. Sci. 23, (2022).

9.            Donen, A. et al. Evaluation of the Therapeutic Potential of Oral Phycocyanin-Rich Spiruli-na Extracts in Neuropsychiatric Disorders. Nat. Prod. J. 12, 76–81 (2022).

10.          Similon, M. V. M. et al. Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. Eur. Neuropsychopharmacol. 60, 91–99 (2022).

11.          Trubetskoy, V. et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature 604, 502–508 (2022).

12.          Matzopoulos, R., Morlock, R., Morlock, A., Lerer, B. & Lerer, L. Corrigendum: Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes (Front. Psychiatry., (2022), 12, 780696, 10.3389/fpsyt.2021.780696). Front. Psychiatry 13, (2022).

13.          Alkelai, A. et al. The benefit of diagnostic whole genome sequencing in schizophrenia and other psychotic disorders. Mol. Psychiatry 27, 1435–1447 (2022).

14.          Matzopoulos, R., Morlock, R., Morlock, A., Lerer, B. & Lerer, L. Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes. Front. Psychiatry 12, (2022).

15.          Blokland, G. A. M. et al. Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biol. Psychiatry 91, 102–117 (2022).

16.          Moskovich, D. et al. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. Oncogene 40, 6248–6257 (2021).

17.          Ni, G. et al. A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts. Biol. Psychiatry 90, 611–620 (2021).

18.          Taliaz, D. et al. Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data. Transl. Psychiatry 11, (2021).

19.          Moskovich, D. et al. DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer. Cancer Lett. 501, 224–233 (2021).

20.          Hess, J. L. et al. A polygenic resilience score moderates the genetic risk for schizophrenia. Mol. Psychiatry 26, 800–815 (2021).

21.          Kamitaki, N. et al. Complement genes contribute sex-biased vulnerability in diverse disorders. Nature 582, 577–581 (2020).

22.          Krol, F. J. et al. Placebo—To be or not to be? Are there really alternatives to placebo-controlled trials? Eur. Neuropsychopharmacol. 32, 1–11 (2020).

23.          Lee, P. H. et al. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell 179, 1469-1482.e11 (2019).

24.          Alkelai, A. et al. New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. Prog. Neuro-Psychopharmacology Biol. Psychiatry 94, (2019).

25.          Huckins, L. M. et al. Publisher Correction: Gene expression imputation across multiple brain regions provides insights into schizophrenia risk (Nature Genetics, (2019), 51, 4, (659-674), 10.1038/s41588-019-0364-4). Nat. Genet. 51, 1068 (2019).

26.          Ben-Ari, H. et al. White matter lesions, cerebral inflammation and cognitive function in a mouse model of cerebral hypoperfusion. Brain Res. 1711, 193–201 (2019).

27.          Huckins, L. M. et al. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. Nat. Genet. 51, 659–674 (2019).

28.          Harold, D. et al. Population-based identity-by-descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 180, 223–231 (2019).

29.          Ni, G. et al. Age at first birth in women is genetically associated with increased risk of schizophrenia. Sci. Rep. 8, (2018).

30.          Wolf, G. et al. Effect of chronic unpredictable stress on mice with developmental under-expression of the Ahi1 gene: Behavioral manifestations and neurobiological correlates. Transl. Psychiatry 8, (2018).

31.          Zai, C. C. et al. Investigation of the HSPG2Gene in tardive dyskinesia-new data and meta-analysis. Front. Pharmacol. 9, (2018).

32.          LeBlanc, M. et al. A correction for sample overlap in genome-wide association studies in a polygenic pleiotropy-informed framework. BMC Genomics 19, (2018).

33.          Ruderfer, D. M. et al. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell 173, 1705-1715.e16 (2018).

34.          Ni, G. et al. Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. Am. J. Hum. Genet. 102, 1185–1194 (2018).

35.          Lotan, A. et al. Differential effects of chronic stress in young-adult and old female mice: Cognitive-behavioral manifestations and neurobiological correlates. Mol. Psychiatry 23, 1432–1445 (2018).

36.          Lerer, B. From freud to biology, from genes to medicines: A 40 year perspective. Isr. J. Psychiatry 55, 65–71 (2018).

37.          Sarner-Levin, K. et al. Anorexia nervosa, selflessness, and gender-role identity: A study of daughters and parents. Isr. J. Psychiatry 55, 25–34 (2018).

38.          Eitan, R. et al. One year double blind study of high vs low frequency subcallosal cingulate stimulation for depression. J. Psychiatr. Res. 96, 124–134 (2018).

39.          Wolf, G. et al. Differentially severe cognitive effects of compromised cerebral blood flow in aged mice: Association with myelin degradation and microglia activation. Front. Aging Neurosci. 9, (2017).

40.          Lotan, A. et al. Alterations in the expression of a neurodevelopmental gene exert long-lasting effects on cognitive-emotional phenotypes and functional brain networks: Translational evidence from the stress-resilient Ahi1 knockout mouse. Mol. Psychiatry 22, 884–899 (2017).

41.          McLaughlin, R. L. et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat. Commun. 8, (2017).

42.          Marshall, C. R. et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat. Genet. 49, 27–35 (2017).

43.          Li, M. et al. Convergent Lines of Evidence Support LRP8 as a Susceptibility Gene for Psychosis. Mol. Neurobiol. 53, 6608–6619 (2016).

44.          Johnson, E. C. et al. No Reliable Association between Runs of Homozygosity and Schizophrenia in a Well-Powered Replication Study. PLoS Genet. 12, (2016).

45.          Hagelkruys, D. et al. Adapting a stand-alone computerized cognitive test battery for online use - A case-study in the context of users with special needs. Comput. Human Behav. 63, 757–768 (2016).

46.          Franke, B. et al. Genetic influences on schizophrenia and subcortical brain volumes: Large-scale proof of concept. Nat. Neurosci. 19, 420–431 (2016).

47.          Li, X. et al. Common variants of IRF3 conferring risk of schizophrenia. J. Psychiatr. Res. 64, 67–73 (2015).

48.          Bulik-Sullivan, B. et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 47, 291–295 (2015).

49.          Vilhjálmsson, B. J. et al. Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. Am. J. Hum. Genet. 97, 576–592 (2015).

50.          Greenbaum, L. & Lerer, B. Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson’s disease modifier genes. Front. Neurol. 6, (2015).

51.          Lotan, A. et al. Neural mechanisms underlying stress resilience in Ahi1 knockout mice: Relevance to neuropsychiatric disorders. Mol. Psychiatry 19, 243–252 (2014).

52.          Lotan, A., Lifschytz, T., Lory, O., Goelman, G. & Lerer, B. Amygdalar disconnectivity could underlie stress resilience in the Ahi1 knockout mouse: Conclusions from a resting-state functional MRI study. Mol. Psychiatry 19, 144 (2014).

53.          Gusev, A. et al. Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. Am. J. Hum. Genet. 95, 535–552 (2014).

54.          Luo, X.-J. et al. Convergent lines of evidence support CAMKK2 as a schizophrenia susceptibility gene. Mol. Psychiatry 19, 774–783 (2014).

55.          Ripke, S. et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421–427 (2014).

56.          Baldinger, P. et al. Neurotransmitters and electroconvulsive therapy. J. ECT 30, 116–121 (2014).

57.          Greenbaum, L. et al. Do tardive dyskinesia and l-dopa induced dyskinesia share common genetic risk factors? An exploratory study. J. Mol. Neurosci. 51, 380–388 (2013).

58.          Gesundheit, B. et al. Immunological and autoimmune considerations of Autism Spectrum Disorders. J. Autoimmun. 44, 1–7 (2013).

59.          Greenbaum, L. et al. Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson’s disease. Front. Neurosci. (2013) doi:10.3389/fnins.2013.00052.

60.          Teltsh, O. et al. Erratum: Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree (International Journal of Neuropsychopharmacology (2011) DOI:10.1017/S1461145711001374). Int. J. Neuropsychopharmacol. 16, 1183 (2013).

61.          Greenbaum, L. et al. Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson’s disease age at onset: Gene and smoking status interaction. Park. Relat. Disord. 19, 72–76 (2013).

62.          Greenbaum, L., Alkelai, A., Zozulinsky, P., Kohn, Y. & Lerer, B. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J. 12, 513–520 (2012).

63.          Lifschytz, T. et al. Relationship between Rgs2 gene expression level and anxiety and depression-like behaviour in a mutant mouse model: Serotonergic involvement. Int. J. Neuropsychopharmacol. 15, 1307–1318 (2012).

64.          Levinson, D. F. et al. Genome-wide association study of multiplex schizophrenia pedigrees. Am. J. Psychiatry 169, 963–973 (2012).

65.          Pelov, I. et al. Involvement of PTPN5, the gene encoding the striatal-enriched protein tyrosine phosphatase, in schizophrenia and cognition. Psychiatr. Genet. 22, 168–176 (2012).

66.          Alkelai, A. et al. Erratum: DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population (International Journal of Neuropsychopharmacology (2011) DOI: 10.1017/S1461145711000903). Int. J. Neuropsychopharmacol. 15, 541 (2012).

67.          Greenbaum, L. et al. Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model. Eur. Neuropsychopharmacol. 22, 379–386 (2012).

68.          Greenbaum, L. et al. Erratum: Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients (Psychopharmacology DOI:10.1007/s00213- 011-2499-6). Psychopharmacology (Berl). 220, 643 (2012).

69.          Greenbaum, L. et al. Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. Psychopharmacology (Berl). 220, 519–528 (2012).

70.          Alkelai, A. et al. Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample. PLoS One 7, (2012).

71.          Stein, D. J., Lerer, B. & Stahl, S. Preface. Essent. Evidence-Based Psychopharmacol. Second Ed. viii (2012) doi:10.1017/CBO9780511910395.001.

72.          Stein, D. J., Lerer, B. & Stahl, S. Essential evidence-based psychopharmacology, second edition. Essential Evidence-Based Psychopharmacology, Second Edition (Cambridge University Press, 2012). doi:10.1017/CBO9780511910395.

73.          Lerer, B. & Belmaker, R. H. Conference scene in global personalized medicine: CINP Thematic Meeting on Pharmacogenomics and Personalised Medicine in Psychiatry, Jerusalem, Israel (April 21-23, 2013). Curr. Pharmacogenomics Person. Med. 10, 264 (2012).

74.          Alkelai, A. et al. DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population. Int. J. Neuropsychopharmacol. 15, 459–469 (2012).

75.          Teltsh, O. et al. Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. Int. J. Neuropsychopharmacol. 15, 309–319 (2012).

76.          Alkelai, A. et al. Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family-based, Arab-Israeli sample. FASEB J. 25, 4011–4023 (2011).

77.          Vardi, N. et al. Hyperintensities on T2-weighted images in the basal ganglia of patients with major depression: Cerebral perfusion and clinical implications. Psychiatry Res. - Neuroimaging 192, 125–130 (2011).

78.          Lifschytz, T. et al. Effect of triiodothyronine on antidepressant screening tests in mice and on presynaptic 5-HT 1A receptors: Mediation by thyroid hormone α receptors. J. Pharmacol. Exp. Ther. 337, 494–502 (2011).

79.          Greenbaum, L. et al. Association of Reelin (RELN) single nucleotide polymorphism rs7341475 with prepulse inhibition in the Jewish Israeli population. Biol. Psychiatry 69, e17–e18 (2011).

80.          Rigbi, A., Yakir, A., Sarner-Kanyas, K., Pollak, Y. & Lerer, B. Why do young women smoke VI. A controlled study of nicotine effects on attention: Pharmacogenetic interactions. Pharmacogenomics J. 11, 45–52 (2011).

81.          Isserles, M. et al. Cognitive-emotional reactivation during deep transcranial magnetic stimulation over the prefrontal cortex of depressive patients affects antidepressant outcome. J. Affect. Disord. 128, 235–242 (2011).

82.          Cooper-Kazaz, R., Rigbi, A. & Lerer, B. Targeting remission by 8 weeks: When should supplementation be considered in patients with major depression treated with a specific serotonin reuptake inhibitor? Compr. Psychiatry 52, 9–16 (2011).

83.          Greenbaum, L., Alkelai, A., Rigbi, A., Kohn, Y. & Lerer, B. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia. Mov. Disord. 25, 2809–2817 (2010).

84.          Greenbaum, L. et al. Why do young women smoke? VII COMT as a risk modifying gene for Nicotine dependence - Role of gene-gene interaction, personality, and environmental factors. Hum. Psychopharmacol. 25, 536–542 (2010).

85.          Cooper, R. & Lerer, B. [The use of thyroid hormones in the treatment of depression]. Harefuah 149, 529-534,549,550 (2010).

86.          Torri, F. et al. Fine mapping of AHI1 as a schizophrenia susceptibility gene: From association to evolutionary evidence. FASEB J. 24, 3066–3082 (2010).

87.          Slonimsky, A. et al. Lymphoblast and brain expression of AHI1 and the novel primate-specific gene, C6orf217, in schizophrenia and bipolar disorder. Schizophr. Res. 120, 159–166 (2010).

88.          Eitan, R. et al. The thyroid hormone, triiodothyronine, enhances fluoxetine-induced neurogenesis in rats: Possible role in antidepressant-augmenting properties. Int. J. Neuropsychopharmacol. 13, 553–561 (2010).

89.          Lifschytz, T., Goltser-Dubner, T., Landshut, G. & Lerer, B. Effect of triiodothyronine on 5-HT1A and 5-HT1B receptor expression in rat forebrain and on latency to feed in the novelty suppressed feeding test. Prog. Neuro-Psychopharmacology Biol. Psychiatry 34, 632–638 (2010).

90.          Cooper-Kazaz, R., Cohen, A. & Lerer, B. Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronine. J. Clin. Psychopharmacol. 30, 211–212 (2010).

91.          Greenbaum, L., Pelov, I., Teltsh, O., Lerer, B. & Kohn, Y. No association between regulator of G-protein signaling 9 (RGS9) and schizophrenia in a Jewish population. Psychiatr. Genet. 20, 47–48 (2010).

92.          Ingason, A. et al. A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia. Hum. Mol. Genet. 19, 1379–1386 (2010).

93.          Alkelai, A. et al. Evidence for an interaction of schizophrenia susceptibility loci on chromosome 6q23.3 and 10q24.33-q26.13 in Arab Israeli families. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 150, 914–925 (2009).

94.          Greenbaum, L., Rigbi, A., Teltsh, O. & Lerer, B. Role of genetic variants in the CHRNA5-CHRNA3-CHRNB4 cluster in nicotine dependence risk: Importance of gene-environment interplay. Mol. Psychiatry 14, 828–830 (2009).

95.          Alkelai, A., Greenbaum, L., Rigbi, A., Kanyas, K. & Lerer, B. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl). 206, 491–499 (2009).

96.          Ng, M. Y. M. et al. Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol. Psychiatry 14, 774–785 (2009).

97.          Greenbaum, L. & Lerer, B. Differential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: Recent progress and emerging open questions. Mol. Psychiatry 14, 912–945 (2009).

98.          Cooper-Kazaz, R. et al. Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J. Affect. Disord. 116, 113–116 (2009).

99.          Rigbi, A., Yakir, A., Kanyas, K., Pollak, Y. & Lerer, B. Further support for a role of the His452Tyr variant in 5-HT2A receptor gene in memory functions in humans. Int. J. Neuropsychopharmacol. 12, 723–725 (2009).

100.        Greenbaum, L. et al. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: Protective role of a functional polymorphism in the 3′-untranslated region. Pharmacogenomics J. 9, 103–110 (2009).

101.        Teltsh, O. et al. P.3.18 Mutation screening in a candidate region for schizophrenia on chromosome 20p13. Eur. Neuropsychopharmacol. 19, S77 (2009).

102.        Maes, M. et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: Leads for future research and new drug developments in depression. Metab. Brain Dis. 24, 27–53 (2009).

103.        Eitan, R., Landshut, G. & Lerer, B. Neurochemical effects of electrically induced seizures: Relevance to the antidepressant mechanism of electroconvulsive therapy. in Electroconvulsive and Neuromodulation Therapies 45–74 (Cambridge University Press, 2009). doi:10.1017/CBO9780511576393.004.

104.        Papakostas, G. I. et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: A quantitative synthesis of double-blind studies. Int. Clin. Psychopharmacol. 24, 19–25 (2009).

105.        Thomas, P. et al. Correlates of response to Olanzapine in a North Indian Schizophrenia sample. Psychiatry Res. 161, 275–283 (2008).

106.        Lerer, B. IJNP: A decade in perspective. Int. J. Neuropsychopharmacol. 11, 1035–1036 (2008).

107.        Gesundheit, B. et al. Sudden psychotic symptoms in a 28-year-old male with thymoma. J. Clin. Oncol. 26, 4353–4355 (2008).

108.        Kohn, Y. et al. Cerebral perfusion after a 2-year remission in major depression. Int. J. Neuropsychopharmacol. 11, 837–843 (2008).

109.        Ludewick, H. P. et al. No support for an association with TAAR6 and schizophrenia in a linked population of European ancestry. Psychiatr. Genet. 18, 208–210 (2008).

110.        Cooper-Kazaz, R. & Lerer, B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int. J. Neuropsychopharmacol. 11, 685–699 (2008).

111.        Canetti, L., Kanyas, K., Lerer, B., Latzer, Y. & Bachar, E. Anorexia nervosa and parental bonding: The contribution of parent-grandparent relationships to eating disorder psychopathology. J. Clin. Psychol. 64, 703–716 (2008).

112.        Smith, R. C., Segman, R. H., Golcer-Dubner, T., Pavlov, V. & Lerer, B. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J. 8, 228–236 (2008).

113.        Bachar, E. et al. Depressive tendencies and lower levels of self-sacrifice in mothers, and selflessness in their anorexic daughters. Eur. Eat. Disord. Rev. 16, 184–190 (2008).

114.        Teltsh, O. et al. Genome-wide linkage scan, fine mapping, and haplotype analysis in a large, inbred, arab israeli pedigree suggest a schizophrenia susceptibility locus on chromosome 20p13. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 147, 209–215 (2008).

115.        Rigbi, A. et al. Why do young women smoke? V. Role of direct and interactive effects of nicotinic cholinergic receptor gene variation on neurocognitive function. Genes, Brain Behav. 7, 164–172 (2008).

116.        Schwab, S. G. et al. DNA sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: An association study. Psychiatr. Genet. 18, 25–30 (2008).

117.        Srivastava, V., Deshpande, S. N., Nimgaonkar, V. L., Lerer, B. & Thelma, B. K. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: Role of metabolic pathway genes. Pharmacogenomics 9, 1055–1068 (2008).

118.        Lerer, B. & Isserles, M. From Meduna to ultrabrief: New directions for the oldest brain stimulation therapy. Brain Stimul. 1, 84–85 (2008).

119.        Pae, C.-U. et al. Association of the trace amine associated receptor 6 (TAAR6) gene with schizophrenia and bipolar disorder in a Korean case control sample. J. Psychiatr. Res. 42, 35–40 (2008).

120.        Tiwari, A. K., Deshpande, S. N., Lerer, B., Nimgaonkar, V. L. & Thelma, B. K. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C > T polymorphism. Pharmacogenomics J. 7, 305–311 (2007).

121.        Massat, I. et al. HTR2C (cys23ser) polymorphism influences early onset in bipolar patients in a large European multicenter association study [3]. Mol. Psychiatry 12, 797–798 (2007).

122.        Kohn, Y. et al. 99mTc-HMPAO SPECT study of cerebral perfusion after treatment with medication and electroconvulsive therapy in major depression. J. Nucl. Med. 48, 1273–1278 (2007).

123.        Greenbaum, L. et al. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet. Genomics 17, 519–528 (2007).

124.        Segman, R. H. et al. Why do young women smoke? IV. Role of genetic variation in the dopamine transporter and lifetime traumatic experience. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 144, 533–540 (2007).

125.        Cooper-Kazaz, R. et al. Combined treatment with sertraline and liothyronine in major depression: A randomized, double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 64, 679–688 (2007).

126.        Strous, R. D. et al. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. Int. J. Neuropsychopharmacol. 10, 321–333 (2007).

127.        Thelma, B. K., Tiwari, A. K., Deshpande, S. N., Lerer, B. & Nimgaonkar, V. L. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: Role of oxidative stress pathway genes. Schizophr. Res. 92, 278–279 (2007).

128.        Morar, B. et al. Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 144, 318–324 (2007).

129.        Yakir, A. et al. Why do young women smoke? III. Attention and impulsivity as neurocognitive predisposing factors. Eur. Neuropsychopharmacol. 17, 339–351 (2007).

130.        Amann-Zalcenstein, D. et al. Erratum: AHI1, a pivotal neurodevelopment gene, and C6orf217 are associated with susceptibility to schizophrenia (European Journal of Human Genetics (2006) vol. 14 (1111-1119) 10.1038/sj.ejhg.5201675). Eur. J. Hum. Genet. 15, 387 (2007).

131.        Lerer, B. IJNP Editorial Board: Meeting new challenges. Int. J. Neuropsychopharmacol. 10, 1–2 (2007).

132.        Krausz, Y. et al. Brain SPECT study of common ground between hypothyroidism and depression. Int. J. Neuropsychopharmacol. 10, 99–106 (2007).

133.        Schwab, S. G. et al. Evidence for association of DNA sequence variants in the phosphatidylinositol-4-phosphate 5-kinase IIα gene (PIP5K2A) with schizophrenia. Mol. Psychiatry 11, 837–846 (2006).

134.        Lerer, E., Kanyas, K., Karni, O., Ebstein, R. P. & Lerer, B. Why do young women smoke? II. Role of traumatic life experience, psychological characteristics and serotonergic genes. Mol. Psychiatry 11, 771–781 (2006).

135.        Eitan, R. & Lerer, B. Nonpharmacological, somatic treatments of depression: Electroconvulsive therapy and novel brain stimulation modalities. Dialogues Clin. Neurosci. 8, 241–258 (2006).

136.        Lerer, B. & Segman, R. H. Pharmacogenetics of antipsychotic therapy: Pivotal research issues and the prospects for clinical implementation. Dialogues Clin. Neurosci. 8, 85–94 (2006).

137.        Greenbaum, L. et al. Localization of SNPs in the CHRNB2 gene. Mol. Psychiatry 11, 223 (2006).

138.        Cheng, R. et al. Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol. Psychiatry 11, 252–260 (2006).

139.        Greenbaum, L. et al. Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes. Mol. Psychiatry 11, 312–322 (2006).

140.        Lerer, B. Recent strategies for potentiation and facilitation of antidepressant treatment: Introduction. Curr. Drug Targets 7, 137 (2006).

141.        Lifschytz, T. et al. Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr. Drug Targets 7, 203–210 (2006).

142.        Amann, D. et al. The trace amine receptor 4 gene is not associated with schizophrenia in a sample linked to chromosome 6q23 [3]. Mol. Psychiatry 11, 119–121 (2006).

143.        Lifschytz, T., Shalom, G., Lerer, B. & Newman, M. E. Sex-dependent effects of fluoxetine and triiodothyronine in the forced swim test in rats. Eur. Neuropsychopharmacol. 16, 115–121 (2006).

144.        Amann-Zalcenstein, D. et al. AHI1, a pivotal neurodevelopmental gene, and C6orf217 are associated with susceptibility to schizophrenia. Eur. J. Hum. Genet. 14, 1111–1119 (2006).

145.        Srivastava, V. et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet. Genomics 16, 111–117 (2006).

146.        Kohn, Y. & Lerer, B. Excitement and confusion on chromosome 6q: The challenges of neuropsychiatric genetics in microcosm. Mol. Psychiatry 10, 1062–1073 (2005).

147.        Schwab, S. G. et al. Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of european sib-pair families. Biol. Psychiatry 58, 446–450 (2005).

148.        Deshpande, S. N. et al. II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatr. Genet. 15, 157–158 (2005).

149.        Lerer, B. et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int. J. Neuropsychopharmacol. 8, 411–425 (2005).

150.        Levi, A. et al. Fine mapping of a schizophrenia susceptibility locus at chromosome 6q23: Increased evidence for linkage and reduced linkage interval. Eur. J. Hum. Genet. 13, 763–771 (2005).

151.        Tiwari, A. K. et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr. Res. 75, 21–26 (2005).

152.        Tiwari, A. K. et al. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J. 5, 60–69 (2005).

153.        Lifschytz, T., Gur, E., Lerer, B. & Newman, M. E. Erratum: Effects of triiodothyronine and fluoxetine on 5-HT1A and 5-HT1B autoreceptor activity in rat brain: Regional differences (Journal of Neuroscience Methods (2004) 140 (133-139) PII: S0165-0270(04)00290-0 and DOI: 10.1016/j.jneumeth.2004.03.028). J. Neurosci. Methods 141, 335 (2005).

154.        Ozdemir, V. & Lerer, B. Pharmacogenomics and the promise of personalized medicine. in Pharmacogenomics, Second Edition 13–50 (CRC Press, 2005).

155.        McQueen, M. B. et al. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am. J. Hum. Genet. 77, 582–595 (2005).

156.        Weiser, M. et al. Sensitivity of ICD-10 diagnosis of psychotic disorders in the Israeli National Hospitalization Registry compared with RDC diagnoses based on SADS-L. Compr. Psychiatry 46, 38–42 (2005).

157.        Lifschytz, T., Gur, E., Lerer, B. & Newman, M. E. Effects of triiodothyronine and fluoxetine on 5-HT1A and 5-HT1B autoreceptor activity in rat brain: Regional differences. J. Neurosci. Methods 140, 133–139 (2004).

158.        Park, N. et al. Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schipzoprenia. Mol. Psychiatry 9, 1091–1099 (2004).

159.        Gur, E., Lifschytz, T., Van De Kar, L. D., Lerer, B. & Newman, M. E. Effects of triiodothyronine on 5-HT1A and 5-HT1B autoreceptor activity, and postsynaptic 5-HT1A receptor activity, in rat hypothalamus: Lack of interaction with imipramine. Psychoneuroendocrinology 29, 1172–1183 (2004).

160.        Gur, E., Lerer, B., Van De Kar, L. D. & Newman, M. E. Chronic rTMS induces subsensitivity of post-synaptic 5-HT1A receptors in rat hypothalamus. Int. J. Neuropsychopharmacol. 7, 335–340 (2004).

161.        Bah, J. et al. Maternal transmission disequilibrium of the glutamate receptor GRIK2 in schizophrenia. Neuroreport 15, 1987–1991 (2004).

162.        Kohn, Y. et al. Linkage disequlibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: Findings from identity by descent haplotype sharing analysis. Am. J. Med. Genet. - Neuropsychiatr. Genet. 128 B, 65–70 (2004).

163.        Mendlewicz, J. et al. Serotonin transporter 5HTTLPR polymorphism and affective disorders: No evidence of association in a large European multicentre study. Eur. J. Hum. Genet. 12, 377–382 (2004).

164.        Blairy, S. et al. Social adjustment and self-esteem of bipolar patients: A multicentric study. J. Affect. Disord. 79, 97–103 (2004).

165.        Siegfried, Z. et al. Association Study of Cannabinoid Receptor Gene (CNR1) Alleles and Anorexia Nervosa: Differences between Restricting and Bingeing/Purging Subtypes. Am. J. Med. Genet. - Neuropsychiatr. Genet. 125 B, 126–130 (2004).

166.        Kanyas, K. et al. Illness Recognition and Disruptiveness in Psychotic Illness. Compr. Psychiatry 45, 109–113 (2004).

167.        Schwab, S. G. et al. Association of tumor necrosis factor alpha gene -G308A polymorphism with schizophrenia. Schizophr. Res. 65, 19–25 (2003).

168.        Bonne, O. et al. Cerebral blood flow in chronic symptomatic mild traumatic brain injury. Psychiatry Res. - Neuroimaging 124, 141–152 (2003).

169.        Segman, R. H. et al. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J. 3, 277–283 (2003).

170.        Lerer, B. Evidence-based psychopharmacology series. Int. J. Neuropsychopharmacol. 6, 301 (2003).

171.        Lerer, B. et al. Genome scan of Arab Israeli families maps a schizophrenia susceptibility gene to chromosome 6q23 and supports a locus at chromosome 10q24. Mol. Psychiatry 8, 488–498 (2003).

172.        Liu, J. et al. Evidence for a putative bipolar disorder locus on 2p13-16 and other potential loci on 4q31, 7q34, 8q13, 9q31, 10q21-24, 13q32, 14q21 and 17q11-12. Mol. Psychiatry 8, 333–342 (2003).

173.        Agid, O. & Lerer, B. Algorithm-based treatment of major depression in an outpatient clinic: Clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int. J. Neuropsychopharmacol. 6, 41–49 (2003).

174.        Lichtigfeld, F. J., Gillman, M. A., Lerer, B. & Macciardi, F. Another marker for different types of depression [3] (multiple letters). Int. J. Neuropsychopharmacol. 6, 91–93 (2003).

175.        Bonne, O. et al. Cerebral blood flow in depressed patients: A methodological comparison of statistical parametric mapping and region of interest analyses. Psychiatry Res. - Neuroimaging 122, 49–57 (2003).

176.        Lerer, B. & Macciardi, F. Reply to Lichtigfeld and Gillman. Int. J. Neuropsychopharmacol. 6, 93 (2003).

177.        Kohn, Y. & Lerer, B. Methodological Advances in Psychiatric Genetics. in Handbook of Medical Psychiatry 13–24 (Taylor and Francis, 2003). doi:10.3109/9780203912485-7.

178.        Rigbi, A., Shalev-Mevorach, L., Taller, A., Taller, Y. & Lerer, B. Relationship of clinical and demographic characteristics of schizophrenia patients to rehabilitation status. Isr. J. Psychiatry Relat. Sci. 40, 258–267 (2003).

179.        Agid, R., Levin, T., Gomori, J. M., Lerer, B. & Bonne, O. T2-weighted image hyperintensities in major depression: Focus on the basal ganglia. Int. J. Neuropsychopharmacol. 6, 215–224 (2003).

180.        Dremencov, E., Gur, E., Lerer, B. & Newman, M. E. Effects of chronic antidepressants and electroconvulsive shock on serotonergic neurotransmission in the rat hippocampus. Prog. Neuro-Psychopharmacology Biol. Psychiatry 27, 729–739 (2003).

181.        Schwab, S. G. et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet. 72, 185–190 (2003).

182.        Gur, E., Lifschytz, T., Lerer, B. & Newman, M. E. Effects of triiodothyronine and imipramine on basal 5-HT levels and 5-HT1 autoreceptor activity in rat cortex. Eur. J. Pharmacol. 457, 37–43 (2002).

183.        Gur, E. et al. Functional effects of chronic electroconvulsive shock on serotonergic 5-HT1A and 5-HT1B receptor activity in rat hippocampus and hypothalamus. Brain Res. 952, 52–60 (2002).

184.        Dremencov, E., Gur, E., Lerer, B. & Newman, M. E. Effects of chronic antidepressants and electroconvulsive shock on serotonergic neurotransmission in the rat hypothalamus. Prog. Neuro-Psychopharmacology Biol. Psychiatry 26, 1029–1034 (2002).

185.        Lerer, B. & Macciardi, F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: A review of candidate-gene studies and future research directions. Int. J. Neuropsychopharmacol. 5, 255–275 (2002).

186.        Cichon, S. et al. Erratum: A genome screen for genes predisposing to bipolar affecting disorder detects a new susceptibility locus on 8q (Human Molecular Genetics (2001) vol. 10 (2933-2944)). Hum. Mol. Genet. 11, 1685 (2002).

187.        Lerer, B. et al. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27, 105–119 (2002).

188.        Levinson, D. F. et al. No major schizophrenia locus detected on chromosome 1q in a large multicenter sample. Science (80-. ). 296, 739–741 (2002).

189.        Segman, R. H. et al. Angiotensin converting enzyme gene insertion/deletion polymorphism: Case-control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia. Am. J. Med. Genet. - Neuropsychiatr. Genet. 114, 310–314 (2002).

190.        Schwab, S. G. et al. Investigation of linkage and association/linkage disequilibrium of HLA A-, DQA1-, DQB 1-, AND DRB1-alleles in 69 sib-pair- and 89 trio-families with schizophrenia. Am. J. Med. Genet. - Neuropsychiatr. Genet. 114, 315–320 (2002).

191.        Massat, I. et al. Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association study of affective disorders. Am. J. Med. Genet. - Neuropsychiatr. Genet. 114, 177–185 (2002).

192.        Segman, R. H. et al. Interactive effect of cytochrome P450 17α-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol. Psychiatry 51, 261–263 (2002).

193.        Gur, E., Dremencov, E., Van De Kar, L. D., Lerer, B. & Newman, M. E. Effects of chronically administered venlafaxine on 5-HT receptor activity in rat hippocampus and hypothalamus. Eur. J. Pharmacol. 436, 57–65 (2002).

194.        Kohn, Y. & Lerer, B. Genetics of Schizophrenia: A review of linkage findings. Isr. J. Psychiatry Relat. Sci. 39, 240–251 (2002).

195.        Segman, R. H. & Lerer, B. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia [2]. Mol. Psychiatry 7, 137–139 (2002).

196.        Cichon, S. et al. A genome screen for genes predisposing to bipolar affective disorder detects a new susceptibility locus on 8q. Hum. Mol. Genet. 10, 2933–2944 (2001).

197.        Schumacher, J. et al. Fine-mapping of chromosomal region 8q24 in bipolar affective disorder. Am. J. Med. Genet. - Neuropsychiatr. Genet. 105, 610 (2001).

198.        Schwab, S. G. et al. Association of SNPs with schizophrenia on chromosome 10p, a region with previously detected linkage. Am. J. Med. Genet. - Neuropsychiatr. Genet. 105, 562 (2001).

199.        Lerer, B. & Shapira, B. Time-dependent sensitization and ECT [1]. Mol. Psychiatry 6, 500 (2001).

200.        Lerer, B. et al. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol. Psychiatry 6, 579–585 (2001).

201.        Sklar, P. et al. Association analysis of NOTCH4 loci in schizophrenia using family and population-based controls. Nat. Genet. 28, 126–128 (2001).

202.        Cichon, S. et al. A possible susceptibility locus for bipolar affective disorder in chromosomal region 10q25-q26. Mol. Psychiatry 6, 342–349 (2001).

203.        Segman, R. H. et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry 6, 225–229 (2001).

204.        Liu, J. et al. A follow-up linkage study supports evidence for a bipolar affective disorder locus on chromosome 21q22. Am. J. Med. Genet. - Neuropsychiatr. Genet. 105, 189–194 (2001).

205.        Nimgaonkar, V. L. et al. Impact of overlapping recruitment on psychiatric genetic studies. Am. J. Med. Genet. - Neuropsychiatr. Genet. 105, 139–140 (2001).

206.        Souery, D. et al. Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: A Multicenter Association Study. Biol. Psychiatry 49, 405–409 (2001).

207.        Gur, E., Dremencov, E., Lerer, B. & Newman, M. E. Functional effects of corticosterone on 5-HT1A and 5-HT1B receptor activity in rat brain: In vivo microdialysis studies. Eur. J. Pharmacol. 411, 115–122 (2001).

208.        Kohn, Y. et al. Increased prevalence of negative life events in subtypes of major depressive disorder. Compr. Psychiatry 42, 57–63 (2001).

209.        Agid, O., Shalev, A. Y. & Lerer, B. Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. J. Clin. Psychiatry 62, 169–173 (2001).

210.        Parasol, N., Cohen, N., Zemishlany, Z., Lerer, B. & Kosower, N. S. Duffy antigen/receptor for chemokines (DARC): Genotypes in Ashkenazi and non-Ashkenazi Jews in Israel. Hum. Biol. 73, 307–313 (2001).

211.        Newman, M. E. et al. Chronic clomipramine alters presynaptic 5-HT(1B) and postsynaptic 5-HT(1A) receptor sensitivity in rat hypothalamus and hippocampus, respectively. Neuropharmacology 39, 2309–2317 (2000).

212.        Gur, E., Lerer, B., Dremencov, E. & Newman, M. E. Chronic repetitive transcranial magnetic stimulation induces subsensitivity of presynaptic serotonergic autoreceptor activity in rat brain. Neuroreport 11, 2925–2929 (2000).

213.        Segman, R. H. et al. 5-HT2A receptor polymorphism and susceptibility to tardive dyskinesia in patients with chronic schizophrenia. Am. J. Med. Genet. - Neuropsychiatr. Genet. 96, 526 (2000).

214.        Segman, R. H. et al. Additive contribution of DRD3gly and HT2CRser alleles to susceptibility to tardive dyskinesia in patients with chronic schizophrenia. Am. J. Med. Genet. - Neuropsychiatr. Genet. 96, 529–530 (2000).

215.        Cichon, S. et al. Systematic search for susceptibility genes in bipolar affective disorder. Am. J. Med. Genet. - Neuropsychiatr. Genet. 96, 467–468 (2000).

216.        Eckstein, G. N. et al. A genome-wide survey for transmission disequilibrium in schizophrenia. Am. J. Med. Genet. - Neuropsychiatr. Genet. 96, 552–553 (2000).

217.        Liu, J. et al. Further analysis of chromosome 21q22 augments prior evidence for linkage to bipolar affective disorder. Am. J. Med. Genet. - Neuropsychiatr. Genet. 96, 483 (2000).

218.        Schumacher, J. et al. No evidence for an X-chromosomal locus for bipolar affective disorder in 64 German and 4 Israeli families. Am. J. Med. Genet. - Neuropsychiatr. Genet. 96, 548 (2000).

219.        Kanyas, K., Segman, R. H., Agid, O. & Lerer, B. The molecular genetics of cigarette smoking: Demographic and environmental complexities. Am. J. Med. Genet. - Neuropsychiatr. Genet. 96, 505 (2000).

220.        Karni, O., Yakir, A., Kanyas, K., Turetsky, N. & Lerer, B. Age at onset in sibling pairs with schizophrenia and schizoaffective disorder. Am. J. Med. Genet. - Neuropsychiatr. Genet. 96, 505 (2000).

221.        Lerer, B. & Mendlewicz, J. Vaeiability of 5-HT2C receptor CYS23SER polymorphism in European populations and vulnerability to affective disorder. Am. J. Med. Genet. - Neuropsychiatr. Genet. 96, 484 (2000).

222.        Schwab, S. G. et al. Susceptibility locus for schizophrenia on 10p: Searching for a candidate. Am. J. Med. Genet. - Neuropsychiatr. Genet. 96, 461 (2000).

223.        Shapira, B., Newman, M. E., Gelfin, Y. & Lerer, B. Blunted temperature and cortisol responses to ipsapirone in major depression: Lack of enhancement by electroconvulsive therapy. Psychoneuroendocrinology 25, 421–438 (2000).

224.        Newman, M. E., Agid, O., Gur, E. & Lerer, B. Pharmacological mechanisms of T3 augmentation of antidepressant action. Int. J. Neuropsychopharmacol. 3, 187–191 (2000).

225.        Shapira, B., Tubi, N. & Lerer, B. Balancing speed of response to ECT in major depression and adverse cognitive effects: Role of treatment schedule. J. ECT 16, 97–109 (2000).

226.        Agid, O., Kohn, Y. & Lerer, B. Environmental stress and psychiatric illness. Biomed. Pharmacother. 54, 135–141 (2000).

227.        Dremencov, E., Gur, E., Lerer, B. & Newman, M. E. Subchronic fluoxetine administration to rats: Effects on 5-HT autoreceptor activity as measured by in vivo microdialysis. Eur. Neuropsychopharmacol. 10, 229–236 (2000).

228.        Frisch, A. et al. Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Eur. Neuropsychopharmacol. 10, 205–209 (2000).

229.        Hranilovic, D. et al. Serotonin transporter gene and schizophrenia: Evidence for association/linkage disequilibrium in families with affected siblings. Mol. Psychiatry 5, 91–95 (2000).

230.        Levinson, D. F. et al. Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p, and 13q: Schizophrenia linkage collaborative group III. Am. J. Hum. Genet. 67, 652–663 (2000).

231.        Canetti, L. et al. The impact of parental death versus separation from parents on the mental health of Israeli adolescents. Compr. Psychiatry 41, 360–368 (2000).

232.        Segman, R. H. et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2C(ser) and DRD3(gly) alleles to susceptibility. Psychopharmacology (Berl). 152, 408–413 (2000).

233.        Schwab, S. G. et al. A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: Support for loci on chromosome 10p and 6. Mol. Psychiatry 5, 638–649 (2000).

234.        Shapira, B. & Lerer, B. Speed of response to bilateral ECT: An examination of possible predictors in two controlled trials. J. ECT 15, 202–206 (1999).

235.        Souery, D. et al. Tyrosine hydroxylase polymorphism and phenotypic heterogeneity in bipolar affective disorder: A multicenter association study. Am. J. Med. Genet. - Neuropsychiatr. Genet. 88, 527–532 (1999).

236.        Newman, M. E., Li, Q., Gelfin, Y., Van de Kar, L. D. & Lerer, B. Low doses of ipsapirone increase growth hormone but not oxytocin secretion in normal male and female subjects. Psychopharmacology (Berl). 145, 99–104 (1999).

237.        Lerer, B. The neurobiology of ECT: The road ahead. J. ECT 15, 1–4 (1999).

238.        Lerer, B. et al. Possible precipitants of psychiatric hospitalization in patients with major depression: Results from the Jerusalem Collaborative Depression Project. Depress. Anxiety 9, 156–162 (1999).

239.        Lerer, B., Gelfin, Y. & Shapira, B. Neuroendocrine evidence for age-related decline in central serotonergic function. Neuropsychopharmacology 21, 321–322 (1999).

240.        Lerer, B. et al. 5-HT(1A) Receptor function in normal subjects on clinical doses of fluoxetine: Blunted temperature and hormone responses to ipsapirone challenge. Neuropsychopharmacology 20, 628–639 (1999).

241.        Rietschel, M. et al. Application of pharmacogenetics to psychotic disorders: The first consensus conference. Date and Place of Meeting: 12 July 1998, Marriott Hotel, 500 Argyle Street, Glasgow. Schizophr. Res. 37, 191–196 (1999).

242.        Gur, E., Dremencov, E., Lerer, B. & Newman, M. E. Venlafaxine: Acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur. J. Pharmacol. 372, 17–24 (1999).

243.        Bonne, O. et al. Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers. Psychopharmacology (Berl). 143, 24–28 (1999).

244.        Bachar, E., Lerer, B. & Shapira, B. Increment in reminiscing after ECT: Possible connections to neuropsychologic changes [2]. J. ECT 15, 165–166 (1999).

245.        Aita, V. M. et al. A comprehensive linkage analysis of chromosome 21q22 supports prior evidence for a putative bipolar affective disorder locus. Am. J. Hum. Genet. 64, 210–217 (1999).

246.        Segman, R. et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry 4, 247–253 (1999).

247.        Wildenauer, D. B., Schwab, S. G., Maier, W. & Lerer, B. Searching for genes in schizophrenia. Acta Neuropsychiatr. 11, 50–53 (1999).

248.        Wittekindt, O. et al. Association between hSKCa3 and schizophrenia not confirmed by transmission disequilibrium test in 193 offspring/parents trios. Mol. Psychiatry 4, 267–270 (1999).

249.        Agid, O. & Lerer, B. Risperidone augmentation of paroxetine in a case of severe, treatment- refractory obsessive-compulsive disorder without comorbid psychopathology [3]. J. Clin. Psychiatry 60, 55–56 (1999).

250.        Shapira, B. et al. Social adjustment and self-esteem in remitted patients with unipolar and bipolar affective disorder: A case-control study. Compr. Psychiatry 40, 24–30 (1999).

251.        Agid, O. et al. Environment and vulnerability to major psychiatric illness: A case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Mol. Psychiatry 4, 163–172 (1999).

252.        Gur, E., Lerer, B. & Newman, M. E. Chronic clomipramine and triiodothyronine increase serotonin levels in rat frontal cortex in vivo: Relationship to serotonin autoreceptor activity. J. Pharmacol. Exp. Ther. 288, 81–87 (1999).

253.        Morag, M., Morag, A., Reichenberg, A., Lerer, B. & Yirmiya, R. Psychological variables as predictors of rubella antibody titers and fatigue - A prospective, double blind study. J. Psychiatr. Res. 33, 389–395 (1999).

254.        Segman, R. H. et al. Genetic factors in tardive dyskinesia: Possible role of the dopamine transporter. Am. J. Med. Genet. - Neuropsychiatr. Genet. 81, 477 (1998).

255.        Wildenauer, D. B. et al. Association/linkage disequilibrium of G-Olfα in 59 families with schizophrenic index patients in the presence of linkage. Am. J. Med. Genet. - Neuropsychiatr. Genet. 81, 524 (1998).

256.        Liu, J. et al. A genome-wide scan for bipolar affective disorder. Am. J. Med. Genet. - Neuropsychiatr. Genet. 81, 462 (1998).

257.        Segman, R. H. et al. Angiotensin converting enzyme polymorphism in schizophrenia and major affective disorder: Population and family-based association studies. Am. J. Med. Genet. - Neuropsychiatr. Genet. 81, 522–523 (1998).

258.        Wildenauer, D. B. et al. Genome scan for autosomal genes conferring risk to schizophrenia in a German/ Israeli sample. Am. J. Med. Genet. - Neuropsychiatr. Genet. 81, 454 (1998).

259.        Aita, V. M. et al. A follow-up linkage analysis of chromosome 21 continues to provide evidence for a putative bipolar affective disorder locus. Am. J. Med. Genet. - Neuropsychiatr. Genet. 81, 476 (1998).

260.        Hallmayer, J. et al. A potential susceptibility locus for schizophrenia on 22q12,13: Re-evaluation in 72 families. Am. J. Med. Genet. - Neuropsychiatr. Genet. 81, 529 (1998).

261.        Freymann, J. et al. Association studies of HLA genes in families with linkage to chromosome 6p. Am. J. Med. Genet. - Neuropsychiatr. Genet. 81, 517 (1998).

262.        Schwab, S. G. et al. A potential susceptibility locus on chromosome 10p14-p11 in 72 families with schizophrenia. Am. J. Med. Genet. - Neuropsychiatr. Genet. 81, 528–529 (1998).

263.        Newman, M. E., Gur, E., Shapira, B. & Lerer, B. Neurochemical mechanisms of action of ECS: Evidence from in vivo studies. J. ECT 14, 153–171 (1998).

264.        Lerer, B. The neurobiology of ECT: The road taken. J. ECT 14, 149–152 (1998).

265.        Krausz, Y. et al. Age-related changes in brain perfusion of normal subjects detected by 99mTc-HMPAO SPECT. Neuroradiology 40, 428–434 (1998).

266.        Vallada, H. P. et al. A transmission disequilibrium and linkage analysis of D22S278 marker alleles in 574 families: Further support for a susceptibility locus for schizophrenia at 22q12. Schizophr. Res. 32, 115–121 (1998).

267.        Schwab, S. G. et al. Further evidence for a susceptibility locus on chromosome 10p14-p11 in 72 families with Schizophrenia by nonparametric linkage analysis. Am. J. Med. Genet. - Neuropsychiatr. Genet. 81, 302–307 (1998).

268.        Morag, M., Yirmiya, R., Lerer, B. & Morag, A. Influence of socioeconomic status on behavioral, emotional and cognitive effects of rubella vaccination: A prospective, double blind study. Psychoneuroendocrinology 23, 337–351 (1998).

269.        Gelfin, Y., Gorfine, M. & Lerer, B. Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am. J. Psychiatry 155, 290–292 (1998).

270.        Lerer, B., Frazer, A., Stahl, S., Farde, L. & Lesch, P. The International Journal of Neuropsychopharmacology. Int. J. Neuropsychopharmacol. 1, 1–2 (1998).

271.        Knowles, J. A. et al. No evidence for significant linkage between bipolar affective disorder and chromosome 18 pericentromeric markers in a large series of multiplex extended pedigrees. Am. J. Hum. Genet. 62, 916–924 (1998).

272.        Schwab, S. G. et al. Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis. Am. J. Hum. Genet. 63, 1139–1152 (1998).

273.        Shapira, B. et al. Cost and benefit in the choice of ECT schedule: Twice versus three times weekly ECT. Br. J. Psychiatry 172, 44–48 (1998).

274.        Souery, D. et al. European Collaborative Project on Affective Disorders: Interactions between genetic and psychosocial vulnerability factors. Psychiatr. Genet. 8, 197–205 (1998).

275.        Newman, M. E., Shapira, B. & Lerer, B. Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: A critical review. Int. J. Neuropsychopharmacol. 1, 49–69 (1998).

276.        Amar, A. et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. Int. J. Neuropsychopharmacol. 1, 41–44 (1998).

277.        Gur, E., Berman, E., Lerer, B. & Newman, M. E. In vivo cyclic AMP responses in rat brain are not modified by chronic electroconvulsive shock. Eur. Neuropsychopharmacol. 7, 189–193 (1997).

278.        Dann, J. et al. A linkage study of schizophrenia to markers within Xp11 near the MAOB gene. Psychiatry Res. 70, 131–143 (1997).

279.        Bloch, M., Schwartzman, Y., Bonne, O. & Lerer, B. Concurrent treatment of nonresistant major depression with desipramine and lithium: A double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 17, 44–48 (1997).

280.        Kohn, Y. et al. Dopamine D4 receptor gene polymorphisms: Relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur. Neuropsychopharmacol. 7, 39–43 (1997).

281.        Kotler, M. et al. Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Mol. Psychiatry 2, 251–254 (1997).

282.        Schwab, S. G. et al. Evidence suggestive of a locus on chromosome 5q31 contributing to susceptibility for schizophrenia in German and Israeli families by multipoint affected sib-pair linkage analysis. Mol. Psychiatry 2, 156–160 (1997).

283.        Ebstein, R. P. et al. Evidence for an association between the dopamine d3 receptor gene DRD3 and schizophrenia. Hum. Hered. 47, 6–16 (1997).

284.        Lerer, B. & Segman, R. H. Correspondence regarding German psychiatric genetics and Ernst Rüdin. Am. J. Med. Genet. 74, 459–463 (1997).

285.        Heresco-Levy, U., Greenberg, D., Lerer, B., Javitt, D. C. & Brown, W. A. Serum Neuroleptic Levels during Reduced Dose Fluphenazine Decanoate Maintenance Therapy. Isr. J. Psychiatry Relat. Sci. 34, 281–289 (1997).

286.        Bleich, A., Koslowsky, M., Dolev, A. & Lerer, B. Post-traumatic stress disorder and depression: An analysis of comorbidity. Br. J. Psychiatry 170, 479–482 (1997).

287.        Segman, R. H. et al. Schizophrenia, chronic hospitalization and the 5-HT(2C) receptor gene. Psychiatr. Genet. 7, 75–78 (1997).

288.        Gur, E., Lerer, B. & Newman, M. E. Chronic electroconvulsive shock and 5-HT autoreceptor activity in rat brain: An in vivo microdialysis study. J. Neural Transm. 104, 795–804 (1997).

289.        Schreiber, S. & Lerer, B. ‘Failure to thrive’ in elderly depressed patients: A new concept or a different name for an old problem? Isr. J. Psychiatry Relat. Sci. 34, 108–114 (1997).

290.        Bonne, O. et al. Cerebral hypoperfusion in medication resistant, depressed patients assessed by Tc99m HMPAO SPECT. J. Affect. Disord. 41, 163–171 (1996).

291.        Petrides, G., Fink, M., Shapira, B. & Lerer, B. Choosing a dosing strategy for electrical stimulation in ECT [3]. J. Clin. Psychiatry 57, 487–488 (1996).

292.        Bonne, O. et al. Increased cerebral blood flow in depressed patients responding to electroconvulsive therapy. J. Nucl. Med. 37, 1075–1080 (1996).

293.        Rifkin, A., Selzer, J. A., Lerer, B. & Shapira, B. ECT sessions: How many a week? [16]. Am. J. Psychiatry 153, 585–586 (1996).

294.        Lerer, B. et al. Interrelationship of age, depression, and central serotonergic function: Evidence from fenfluramine challenge studies. Int. Psychogeriatrics 8, 83–102 (1996).

295.        Wildenauer, D. B. et al. Searching for susceptibility genes in schizophrenia by genetic linkage analysis. Cold Spring Harbor Symposia on Quantitative Biology vol. 61 845–850 (1996).

296.        Maier, W. et al. Genetic relationship between dopamine transporter gene and schizophrenia: Linkage and association. Schizophr. Res. 20, 175–180 (1996).

297.        Shapira, B., Lidsky, D., Gorfine, M. & Lerer, B. Electroconvulsive therapy and resistant depression: Clinical implications of seizure threshold. J. Clin. Psychiatry 57, 32–38 (1996).

298.        Gur, E., Lerer, B. & Newman, M. E. Acute or chronic lithium does not affect agonist-stimulated inositol trisphosphate formation in rat brain in vivo. Neuroreport 7, 393–396 (1996).

299.        Krausz, Y. et al. Brain SPECT imaging of neuropsychiatric disorders. Eur. J. Radiol. 21, 183–187 (1996).

300.        Wildenauer, D. B. et al. Additional Support for Schizophrenia Linkage on Chromosomes 6 and 8: A Multicenter Study. Am. J. Med. Genet. 67, 580–594 (1996).

301.        Schwab, S. G. et al. Potential linkage for schizophrenia on chromosome 22q12-q13: A replication study. Am. J. Med. Genet. - Neuropsychiatr. Genet. 60, 436–443 (1995).

302.        Gelfin, Y., Lerer, B., Lesch, K. P., Gorfine, M. & Allolio, B. Complex effects of age and gender on hypothermic, adrenocorticotrophic hormone and cortisol responses to ipsapirone challenge in normal subjects. Psychopharmacology (Berl). 120, 356–364 (1995).

303.        Segman, R. H., Gorfine, M., Lerer, B. & Shapira, B. Onset and time course of antidepressant action: psychopharmacological implications of a controlled trial of electroconvulsive therapy. Psychopharmacology (Berl). 119, 440–448 (1995).

304.        Kohn, Y., Newman, M. E., Lerer, B., Orr, S. P. & Pitman, R. K. Absence of reduced platelet adenylate cyclase activity in Vietnam veterans with PTSD. Biol. Psychiatry 37, 205–208 (1995).

305.        Heresco-Levy, U., Greenberg, D., Lerer, B., Dasberg, H. & Brown, W. A. Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse. Isr. J. Psychiatry Relat. Sci. 32, 268–275 (1995).

306.        Lerer, B. Biological psychiatry in Israel: approaching the challenge of maturity. Isr. J. Psychiatry Relat. Sci. 32, 1–4 (1995).

307.        Shapira, B., Gorfine, M. & Lerer, B. A prospective study of lithium continuation therapy in depressed patients who have responded to electroconvulsive therapy. Convuls. Ther. 11, 80–85 (1995).

308.        Devanand, D. P. et al. Effects of electroconvulsive therapy on plasma GABA. Convuls. Ther. 11, 3–13 (1995).

309.        Alexander, J. R., Benjamin, J., Lerer, B., Baron, M. & Belmaker, R. H. Frequency of positive family history in bipolar patients in a catchment-area population. Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 367–373 (1995).

310.        Mulcrone, J. et al. Genetic linkage analysis of schizophrenia using chromosome 11q13-24 markers in Israeli pedigrees. Am. J. Med. Genet. - Neuropsychiatr. Genet. 60, 103–108 (1995).

311.        Lerer, B. et al. Antidepressant and cognitive effects of twice-versus three-times-weekly ECT. Am. J. Psychiatry 152, 564–570 (1995).

312.        Kosower, N. S. et al. Constitutive heterochromatin of chromosome 1 and Duffy blood group alleles in schizophrenia. Am. J. Med. Genet. - Neuropsychiatr. Genet. 60, 133–138 (1995).

313.        Schwab, S. G. et al. Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib–pair linkage analysis. Nat. Genet. 11, 325–327 (1995).

314.        Shapira, B., Newman, M. & Lerer, B. Serotonergic mechanisms in depression: Clinical insights and biological correlates. Isr. J. Med. Sci. 30, 162–167 (1994).

315.        Bloch, M., Schwartzmann, Y., Bonne, O. & Lerer, B. Does concurrent lithium administration potentiate the antidepressant effect of desipramine? Eur. Neuropsychopharmacol. 4, 299–300 (1994).

316.        Segman, R., Newman, M. E. & Lerer, B. Serotonin stimulation of GTP binding in rat hippocampal membranes and the action of antidepressant drugs. Eur. Neuropsychopharmacol. 4, 318 (1994).

317.        Heresco-Levy, U., Lerer, B., Greenberg, D., Javitt, D. C. & Brown, W. A. Serum levels of fluphenazine in schizophrenic outpatients maintained on two reduced doses of fluphenazine decanoate. Eur. Neuropsychopharmacol. 4, 385–386 (1994).

318.        Bonne, O. B. et al. Cerebral blood flow in symptomatic closed cranial injury patients. Eur. Neuropsychopharmacol. 4, 442 (1994).

319.        Gur, E., Rogel-Fuchs, Y., Newman, M. E. & Lerer, B. Effects of antidepressants on cyclic AMP responses in the living rat. Eur. Neuropsychopharmacol. 4, 317–318 (1994).

320.        Gelfin, G., Lesch, K. P. & Lerer, B. Effect of normal aging on 5-HT1A receptor mediated temperature and hormone responses. Eur. Neuropsychopharmacol. 4, 406–407 (1994).

321.        Shapira, B., Gorfine, M., Lidsky, D. & Lerer, B. Seizure threshold and the treatment of major depression by electroconvulsive therapy. Eur. Neuropsychopharmacol. 4, 300–301 (1994).

322.        Lerer, B. & Shapira, B. How resistant is resistant depression? Focus on electroconvulsive therapy. Eur. Neuropsychopharmacol. 4, 211–212 (1994).

323.        Bleich, A., Dolev, A., Koslowski, M., Vozner, Y. & Lerer, B. Psychiatric morbidity following psychic trauma of combat origin. Harefuah 126, 493-496,562 (1994).

324.        Weizmann, R. et al. Platelet adenylate cyclase activity in israeli victims of iraqi Scud missile attacks with post-traumatic stress disorder. Psychopharmacology (Berl). 114, 509–512 (1994).

325.        Baron, M. et al. A pedigree series for mapping disease genes in bipolar affective disorder: Sampling, assessment, and analytic considerations. Psychiatr. Genet. 4, 43–55 (1994).

326.        Baron, M. et al. Bipolar disorder and linkage to Xq28. Nat. Genet. 7, 461 (1994).

327.        Straub, R. E. et al. A possible vulnerability locus for bipolar affective disorder on chromosome 21q22.3. Nat. Genet. 8, 291–296 (1994).

328.        Bloch, M. & Lerer, B. Temporal changes in depression during the 20th century: is the world heading toward an era of depression? Harefuah 125, 412–415 (1993).

329.        Shapira, B., Cohen, J., Newman, M. E. & Lerer, B. Prolactin response to fenfluramine and placebo challenge following maintenance pharmacotherapy withdrawal in remitted depressed patients. Biol. Psychiatry 33, 531–535 (1993).

330.        Baron, M. et al. Diminished support for linkage between manic depressive illness and X–chromosome markers in three Israeli pedigrees. Nat. Genet. 3, 49–55 (1993).

331.        Zervas, I. M. et al. Age-dependent effects of electroconvulsive therapy on memory. Convuls. Ther. 9, 39–42 (1993).

332.        Heresco-Levy, U., Greenberg, D., Lerer, B., Dasberg, H. & Brown, W. A. Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: Two-year outcome. J. Clin. Psychiatry 54, 59–62 (1993).

333.        Silver, H. et al. Factor analysis of schizophrenic symptoms and comparison of different rating scales. Schizophr. Res. 10, 67–75 (1993).

334.        Tubi, N. et al. Subjective symptoms in depression and during the course of electroconvulsive therapy. Neuropsychiatry, Neuropsychol. Behav. Neurol. 6, 187–192 (1993).

335.        Newman, M. E., Lerer, B. & Shapira, B. 5-HT-1A receptor-mediated effects of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 17, 1–19 (1993).

336.        Bloch, M., Admon, D., Bonne, O. & Lerer, B. Electroconvulsive therapy in a depressed heart transplant patient. Convuls. Ther. 8, 290–293 (1992).

337.        Newman, M. E., Lerer, B., Lichtenberg, P. & Shapira, B. Platelet adenylate cyclase activity in depression and after clomipramine and lithium treatment: relation to serotonergic function. Psychopharmacology (Berl). 109, 231–234 (1992).

338.        Shapira, B., Yagmur, M. J., Gropp, C., Newman, M. & Lerer, B. Effect of clomipramine and lithium on fenlfuramine-induced hormone release in major depression. Biol. Psychiatry 31, 975–983 (1992).

339.        Lichtenberg, P. et al. Effect of fenfluramine on mood: A double-blind placebo-controlled trial. Biol. Psychiatry 31, 351–356 (1992).

340.        Moscovich, D. G., Shapira, B., Lerer, B. & Belmaker, R. H. Rapid lithiumization in acute manic patients. Hum. Psychopharmacol. Clin. Exp. 7, 343–345 (1992).

341.        Lichtenberg, P. et al. Hormone responses to fenfluramine and placebo challenge in endogenous depression. Psychiatry Res. 43, 137–146 (1992).

342.        Bonne, O., Krausz, Y. & Lerer, B. SPECT imaging in psychiatry. A review. Gen. Hosp. Psychiatry 14, 296–306 (1992).

343.        Newman, M. E., Shapira, B. & Lerer, B. Regulation of 5-hydroxytryptamine(1A) receptor function in rat hippocampus by short- and long-term administration of 5-hydroxytryptamine(1A) agonists and antidepressants. J. Pharmacol. Exp. Ther. 260, 16–20 (1992).

344.        Shapira, B. et al. Enhanced serotonergic responsivity following electroconvulsive therapy in patients with major depression. Br. J. Psychiatry 160, 223–229 (1992).

345.        Alexander, J. R., Lerer, B. & Baron, M. Ethical issues in genetic linkage studies of psychiatric disorders. Br. J. Psychiatry 160, 98–102 (1992).

346.        Shapira, B., Newman, M. & Lerer, B. Serotonergic mechanisms of ECT: neuroendocrine evidence. Clin. Neuropharmacol. 15 Suppl 1 Pt A, 673A-674A (1992).

347.        Silver, H., Blacker, M., Weller, M. P. I. & Lerer, B. Treatment of chronic schizophrenia with cyproheptadine: A double-blind placebo-controlled study. Biol. Psychiatry 30, 523–525 (1991).

348.        Newman, M. E., Ben-Zeev, A. & Lerer, B. Chloroamphetamine did not prevent the effects of chronic antidepressants on 5-hydroxytryptamine inhibition of forskolin-stimulated adenylate cyclase in rat hippocampus. Eur. J. Pharmacol. Mol. Pharmacol. 207, 209–213 (1991).

349.        Bennett, E. R., Yedgar, S., Lerer, B. & Ebstein, R. P. Phospholipase A2 activity in Epstein-Barr virus-transformed lymphoblast cells from schizophrenic patients. Biol. Psychiatry 29, 1058–1062 (1991).

350.        Lesch, K. P. & Lerer, B. The 5-HT receptor - G-protein - effector system complex in depression I. Effect of glucocorticoids. J. Neural Transm. 84, 3–18 (1991).

351.        Shapira, B., Calev, A. & Lerer, B. Optimal use of electroconvulsive therapy: Choosing a treatment schedule. Psychiatr. Clin. North Am. 14, 935–946 (1991).

352.        Calev, A. et al. Change in attitude toward electroconvulsive therapy: Effects of treatment, time since treatment, and severity of depression. Convuls. Ther. 7, 184–189 (1991).

353.        Calev, A. et al. Early and long-term effects of electroconvulsive therapy and depression on memory and other cognitive functions. J. Nerv. Ment. Dis. 179, 526–533 (1991).

354.        Newman, M. E., Shapira, B. & Lerer, B. Effects of lithium and desimipramine on second messenger responses in rat hippocampus: relation to G protein effects. Neuropharmacology 30, 1297–1301 (1991).

355.        Bachar, E., Kindler, S., Schefler, G. & Lerer, B. Reminiscing as a technique in the group psychotherapy of depression: A comparative study. Br. J. Clin. Psychol. 30, 375–377 (1991).

356.        Calev, A., Nigal, D., Kugelmass, S., Weller, M. P. I. & Lerer, B. Performance of long‐stay schizophrenics after drug withdrawal on matched immediate and delayed recall tasks. Br. J. Clin. Psychol. 30, 241–245 (1991).

357.        Calev, A. et al. Atropine and cognitive performance after electroconvulsive therapy. Convuls. Ther. 7, 92–98 (1991).

358.        Kindler, S. et al. Factors influencing response to bilateral electroconvulsive therapy in major depression. Convuls. Ther. 7, 245–254 (1991).

359.        Calev, A. et al. Disorientation and bilateral moderately suprathreshold titrated ECT. Convuls. Ther. 7, 99–110 (1991).

360.        Calev, A., Edelist, S., Kugelmass, S. & Lerer, B. Performance of long-stay schizophrenics on matched verbal and visuospatial recall tasks. Psychol. Med. 21, 655–660 (1991).

361.        Solomon, Z. et al. Post-traumatic stress disorder: Issues of co-morbidity. J. Psychiatr. Res. 25, 89–94 (1991).

362.        Belmaker, R. H., Lerer, B., Newman, M. & Fuchs, I. Lack of effect of lithium, propranolol or haloperidol on basal plasma cyclic AMP levels. Lithium 2, 115–116 (1991).

363.        Nigal, D., Calev, A., Kugelmass, S. & Lerer, B. Effect of four-week neuroleptic and anticholinergic drug withdrawal on memory function in chronic long-hospitalized schizophrenics. Ann. Clin. Psychiatry 3, 141–145 (1991).

364.        Lerer, B., Bleich, A., Bennett, E. R., Ebstein, R. P. & Balkin, J. Platelet adenylate cyclase and phospholipase C activity in posttraumatic stress disorder. Biol. Psychiatry 27, 735–740 (1990).

365.        Newman, M. E., Drummer, D. & Lerer, B. Single and combined effects of desimipramine and lithium on serotonergic receptor number and second messenger function in rat brain. J. Pharmacol. Exp. Ther. 252, 826–831 (1990).

366.        Braun, P., Greenberg, D., Dasberg, H. & Lerer, B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J. Clin. Psychiatry 51, 236–238 (1990).

367.        Bachar, E., Dasberg, H., Shapira, B. & Lerer, B. Reminiscing in depressed, ageing patients: Effect of ECT and antidepressants. Int. J. Geriatr. Psychiatry 5, 251–256 (1990).

368.        Bachar, E., Calev, A., Shapira, B. & Lerer, B. Memories in depression: Pleasant or unpleasant? Br. J. Psychiatry 157, 623–624 (1990).

369.        Ebstein, R. P. et al. Cyclic AMP second messenger signal generation in EBV-transformed lymphoblastoid cells from schizophrenic patients. J. Psychiatr. Res. 24, 121–127 (1990).

370.        Gil, T., Calev, A., Greenberg, D., Kugelmass, S. & Lerer, B. Cognitive functioning in Post-Traumatic Stress Disorder. J. Trauma. Stress 3, 29–45 (1990).

371.        Lerer, B. & Shapira, B. ECT: Twice or thrice a week: Reply. Convuls. Ther. 5, 364–365 (1989).

372.        Heresco-Levy, U., Greenberg, D., Wittman, L., Dasberg, H. & Lerer, B. Prescribing patterns of neuroactive drugs in 98 schizophrenic patients. Isr. J. Psychiatry Relat. Sci. 26, 157–163 (1989).

373.        Newman, M. E. & Lerer, B. Post-receptor-mediated increases in adenylate cyclase activity after chronic antidepressant treatment: relationship to receptor desensitization. Eur. J. Pharmacol. 162, 345–352 (1989).

374.        Silver, H., Blacker, M., Weller, M. P. I. & Lerer, B. Treatment of chronic schizophrenia with cyproheptadine. Biol. Psychiatry 25, 502–504 (1989).

375.        Roth, D., Hamburger-Bar, R. & Lerer, B. Peripheral versus central manifestations in the toxic interaction of lithium and pilocarpine. Biol. Psychiatry 25, 153–158 (1989).

376.        Itzchaky, S., Lerer, B. & Ebstein, R. P. Uptake of 3H-spiperone by lymphocytes in schizophrenia. J. Psychiatr. Res. 23, 221–227 (1989).

377.        Calev, A. et al. Distinct memory impairments following electroconvulsive therapy and imipramine. Psychol. Med. 19, 111–119 (1989).

378.        Shapira, B., Reiss, A., Kaiser, N., Kindler, S. & Lerer, B. Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. J. Affect. Disord. 16, 1–4 (1989).

379.        Newman, M. E. & Lerer, B. Modulation of second messenger function in rat brain by in vivo alteration of receptor sensitivity: Relevance to the mechanism of action of electroconvulisve therapy and antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 13, 1–30 (1989).

380.        Newman, M. E. & Lerer, B. Effects of chronic electroconvulsive shock on D1 and D2 dopamine receptor-mediated activity of adenylate cyclase in homogenates of striatum and limbic forebrain of rat. Neuropharmacology 28, 787–790 (1989).

381.        Lichtenberg, P. & Lerer, B. Implications of clinical spectrum for mechanisms of action: ECT and antidepressants reconsidered. Convuls. Ther. 5, 216–226 (1989).

382.        Newman, M. E. & Lerer, B. Effects of lithium and desipramine administration on agonist-stimulated inositol phosphate accumulation in rat cerebral cortex. Biochem. Pharmacol. 37, 1991–1995 (1988).

383.        Newman, M. E. & Lerer, B. Chronic electroconvulsive shock and desimipramine reduce the degree of inhibition by 5-HT and carbachol of forskolin-stimulated adenylate cyclase in rat hippocampal membranes. Eur. J. Pharmacol. 148, 257–260 (1988).

384.        Lerer, B. et al. Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction. Schizophr. Res. 1, 405–410 (1988).

385.        Shapira, B., Kindler, S. & Lerer, B. Failure to convulse with ECT. Br. J. Psychiatry 153, 413–414 (1988).

386.        Ebstein, R. P. et al. Lithium modulation of second messenger signal amplification in man: Inhibition of phosphatidylinositol- specific phospholipase C and adenylate cyclase activity. Psychiatry Res. 24, 45–52 (1988).

387.        Ebstein, R. P. et al. Cyclic AMP second-messenger signal amplification in depression. Br. J. Psychiatry 152, 665–669 (1988).

388.        Shestatzky, M., Greenberg, D. & Lerer, B. A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res. 24, 149–155 (1988).

389.        Shapira, B., Kindler, S. & Lerer, B. Medication outcome in ECT-resistant depression. Convuls. Ther. 4, 192–198 (1988).

390.        Lichtenberg, P., Navon, R., Wertman, E., Dasberg, H. & Lerer, B. Post-partum psychosis in adult GM2 gangliosidosis: A case report. Br. J. Psychiatry 153, 387–389 (1988).

391.        Chazan, S. et al. A study of the discriminating power of the Wechsler Memory Scale using schizophrenic and normal subjects in Israel. Isr. J. Psychiatry Relat. Sci. 24, 179–190 (1987).

392.        Lerer, B., Moore, N., Meyendorff, E., Cho, S. R. & Gershon, S. Carbamazepine versus lithium in mania: A double-blind study. J. Clin. Psychiatry 48, 89–93 (1987).

393.        Ebstein, R. P., Bennett, E. R., Stessman, J. & Lerer, B. Isoelectric focusing of human platelet phospholipase C: Evidence for multimolecular forms. Life Sci. 40, 161–167 (1987).

394.        Lerer, B. et al. Posttraumatic Stress Disorder in Israeli Combat Veterans: Effect of Phenelzine Treatment. Arch. Gen. Psychiatry 44, 976–981 (1987).

395.        Garb, R., Bleich, A. & Lerer, B. Bereavement in combat. Psychiatr. Clin. North Am. 10, 421–436 (1987).

396.        Newman, M. E., Miskin, I. & Lerer, B. Effects of Single and Repeated Electroconvulsive Shock Administration on Inositol Phosphate Accumulation in Rat Brain Slices. J. Neurochem. 49, 19–23 (1987).

397.        Hamburger-Bar, R., Kindler, S., Bertish, T. & Lerer, B. Conditioned avoidance acquisition and extinction following repeated electroconvulsive shock: Strain effect and response to vasopressin. Biol. Psychiatry 22, 593–602 (1987).

398.        Lerer, B., Ebstein, R. P., Shestatsky, M., Shemesh, Z. & Greenberg, D. Cyclic AMP signal transduction in posttraumatic stress disorder. Am. J. Psychiatry 144, 1324–1327 (1987).

399.        Newman, M. E., Lipot, M. & Lerer, B. Differential effects of chronic administration of desipramine on the cyclic AMP response in cortical slices and membranes in the rat. Neuropharmacology 26, 1127–1130 (1987).

400.        Shapira, B. et al. Facilitation of ECT by caffeine pretreatment. Am. J. Psychiatry 144, 1199–1202 (1987).

401.        Ebstein, R. P., Moscovich, D., Zeevi, S., Amiri, Z. & Lerer, B. Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: Postreceptor modification of second messenger signal amplification. Psychiatry Res. 21, 221–228 (1987).

402.        Calev, A., Korin, Y., Kugelmass, S. & Lerer, B. Performance of chronic schizophrenics on matched word and design recall tasks. Biol. Psychiatry 22, 699–709 (1987).

403.        Calev, A., Berlin, H. & Lerer, B. Remote and recent memory in long-hospitalized chronic schizophrenics. Biol. Psychiatry 22, 79–85 (1987).

404.        Ebstein, R. P. et al. Second messenger function in lymphocytes and platelets: a comparison of peripheral and central mechanisms. Clin. Neuropharmacol. 9 Suppl 4, 350–352 (1986).

405.        Lerer, B., Shapira, B., Drexler, H., Calev, A. & Newman, M. E. Pharmacological manipulation of ECT-induced seizure duration. Clin. Neuropharmacol. 9 Suppl 4, 453–455 (1986).

406.        Calev, A., Korin, Y., Shapira, B., Kugelmass, S. & Lerer, B. Verbal and non verbal recall by depressed and euthymic affective patients. Psychol. Med. 16, 789–794 (1986).

407.        Shapira, B. & Lerer, B. Clinical response rate to ECT. Psychiatry Res. 17, 247–248 (1986).

408.        Newman, M. E., Solomon, H. & Lerer, B. Electroconvulsive Shock and Cyclic AMP Signal Transduction: Effects Distal to the Receptor. J. Neurochem. 46, 1667–1669 (1986).

409.        Lerer, B., Stanley, M., Keegan, M. & Altman, H. Proactive and retroactive effects of repeated electroconvulsive shock on passive avoidance retention in rats. Physiol. Behav. 36, 471–475 (1986).

410.        LERER, B. & SHAPIRA, B. Neurochemical Mechanisms of Mood Stabilization: Focus on Electroconvulsive Therapy. Annals of the New York Academy of Sciences vol. 462 366–375 (1986).

411.        LERER, B., STANLEY, M., ALTMAN, H. & KEEGAN, M. An Animal Model of Electroconvulsive‐Therapy‐Induced Amnesia: Possible Neurochemical Correlates. Annals of the New York Academy of Sciences vol. 462 91–98 (1986).

412.        Bleich, A., Siegel, B., Garb, R. & Lerer, B. Post-traumatic stress disorder following combat exposure: Clinical features and psychopharmacological treatment. Br. J. Psychiatry 149, 365–369 (1986).

413.        Lerer, B., Warner, J., Friedman, E., Vincent, G. & Gamzu, E. Cortical cholinergic impairment and behavioral deficits produced by kainic acid lesions of rat magnocellular basal forebrain. Behav. Neurosci. 99, 661–677 (1985).

414.        Lerer, B., Moore, N., Meyendorff, E., Cho, S. R. & Gershon, S. Carbamazepine and lithium: Different profiles in affective disorder? Psychopharmacol. Bull. 21, 18–22 (1985).

415.        Lerer, B. & Stanley, M. Effect of chronic lithium on cholinergically mediated responses and [3H]QNB binding in rat brain. Brain Res. 344, 211–219 (1985).

416.        Meyendorff, E., Lerer, B., Moore, N. C., Bow, J. & Gershon, S. Methylphenidate infusion in euthymic bipolars: Effect of carbamazepine pretreatment. Psychiatry Res. 16, 303–308 (1985).

417.        Lerer, B. Studies on the role of brain cholinergic systems in the therapeutic mechanisms and adverse effects of ECT and lithium. Biol. Psychiatry 20, 20–40 (1985).

418.        Lerer, B. & Stanley, M. Doe lithium stabilize muscarinic receptors? Biol. Psychiatry 20, 1247–1248 (1985).

419.        Moore, N. C., Lerer, B., Meyendorff, E. & Gershon, S. Three cases of carbamazepine toxicity. Am. J. Psychiatry 142, 974–975 (1985).

420.        Stanley, M. & Lerer, B. Electroconvulsive shock and brain cholinergic function: Role of striatal muscarinic receptors. Convuls. Ther. 1, 158–166 (1985).

421.        Lerer, B. Alternative therapies for bipolar disorder. J. Clin. Psychiatry 46, 309–316 (1985).

422.        Lerer, B., Stanley, M., McIntyre, I. & Altman, H. Electroconvulsive shock and brain muscarinic receptors: Relationship to anterograde amnesia. Life Sci. 35, 2659–2664 (1984).

423.        Lerer, B. ECT and tardive dyskinesia. J. Clin. Psychiatry 45, 188 (1984).

424.        Klein, E., Lerer, B., Newman, M., Belmaker, R. H. & Bhargava, H. N. Effect of cyclo(Leu-Gly) on reserpine-induced hypomotility and increases in cortical β-adrenergic receptors. Psychopharmacology (Berl). 83, 76–78 (1984).

425.        Lerer, B. & Stanley, M. ECT-induced memory impairment – a cholinergic mechanism? Behav. Brain Sci. 7, 29–30 (1984).

426.        Klein, E., Bental, E., Lerer, B. & Belmaker, R. H. Carbamazepine and Haloperidol v Placebo and Haloperidol in Excited Psychoses: A Controlled Study. Arch. Gen. Psychiatry 41, 165–170 (1984).

427.        Lerer, B. Electroconvulsive shock and neurotransmitter receptors: Implications for mechanism of action and adverse effects of electroconvulsive therapy. Biol. Psychiatry 19, 361–383 (1984).

428.        Lerer, B., Globus, M., Brik, E., Hamburger, R. & Belmaker, R. H. Effect of treatment and withdrawal from chronic lithium in rats on stimulant-induced responses. Neuropsychobiology 11, 28–32 (1984).

429.        Lerer, B., Altman, H. & Stanley, M. Enhancement of memory by a cholinesterase inhibitor associated with muscarinic receptor down-regulation. Pharmacol. Biochem. Behav. 21, 467–469 (1984).

430.        Ebstein, R. P., Lerer, B., Shlaufman, M. & Belmaker, R. H. The effect of repeated electroconvulsive shock treatment and chronic lithium feeding on the release of norepinephrine from rat cortical vesicular preparations. Cell. Mol. Neurobiol. 3, 191–201 (1983).

431.        Lerer, B., Stanley, M., Demetriou, S. & Gershon, S. Effect of Electroconvulsive Shock on Muscarinic Cholinergic Receptors in Rat Cerebral Cortex and Hippocampus. J. Neurochem. 41, 1680–1683 (1983).

432.        Lerer, B., Zabow, T., Egnal, N. & Belmaker, R. H. Effect of vasopressin on memory following electroconvulsive therapy. Biol. Psychiatry 18, 821–824 (1983).

433.        Belmaker, R. H. et al. Clinical implications of research on the mechanism of action of lithium. Prog. Neuropsychopharmacol. Biol. Psychiatry 7, 287–296 (1983).

434.        Lerer, B. & Sitaram, N. Clinical strategies for evaluating ect mechanisms - pharmacological, biochemical and psychophysiological approaches. Prog. Neuropsychopharmacol. Biol. Psychiatry 7, 309–333 (1983).

435.        Birmaher, B., Lerer, B. & Belmaker, R. H. Lithium does not prevent ECS-induced decreases in β-adrenergic receptors. Psychopharmacology (Berl). 78, 190–191 (1982).

436.        Lerer, B., Jabotinsky-Rubin, K., Bannet, J., Ebstein, R. P. & Belmaker, R. H. Electroconvulsive shock prevents dopamine receptor supersensitivity. Eur. J. Pharmacol. 80, 131–134 (1982).

437.        Globus, M., Bannet, J., Lerer, B. & Belmaker, R. H. The effect of chronic bromocriptine and l-Dopa on spiperone binding and apomorphine-induced stereotypy. Psychopharmacology (Berl). 78, 81–84 (1982).

438.        Zohar, J., Lerer, B., Ebstein, R. P. & Belmaker, R. H. Lithium does not prevent agonist-induced subsensitivity of human adenylate cyclase. Biol. Psychiatry 17, 343–350 (1982).

439.        Lerer, B. & Belmaker, R. H. Receptors and the mechanism of action of ECT. Biol. Psychiatry 17, 497–511 (1982).

440.        Belmaker, R. H., Lerer, B. & Zohar, J. Salbutamol treatment of depression. Adv. Biochem. Psychopharmacol. 32, 181–193 (1982).

441.        Belmaker, R. H., Lerer, B., Bannet, J. & Birmaher, B. The effect of electroconvulsive shock at a clinically equivalent schedule on rat cortical β‐adrenoceptors. J. Pharm. Pharmacol. 34, 275 (1982).

442.        Lerer, B., Ebstein, R. P. & Belmaker, R. H. Subsensitivity of human β-adrenergic adenylate cyclase after salbutamol treatment of depression. Psychopharmacology (Berl). 75, 169–172 (1981).

443.        Belmaker, R. H., Lerer, B. & Ebstein, R. P. Noradrenaline, dopamine and mood. Adv. Biosci. 31, 17–29 (1981).

444.        Lerer, B. & Jacobowitz, J. Treatment of essential hyperhidrosis by psychotherapy. Psychosomatics 22, 536–538 (1981).

445.        Goldman, Z. et al. Haloperidol blood levels during dosage reduction in chronic schizophrenic patients. Neuropsychobiology 7, 281–284 (1981).

446.        Globus, M., Lerer, B., Hamburger, R. & Belmaker, R. H. Chronic electroconvulsive shock and chronic haloperidol administration are not additive in effects on dopamine receptors. Neuropharmacology 20, 1125–1128 (1981).

447.        Hertz, D. G. & Lerer, B. The ‘rape family’: family reactions to the rape victim. Int. J. Fam. Psychiatry 2, 301–315 (1981).

448.        Bannet, J., Lerer, B., Ebstein, R. P., Ben-David, M. & Belmaker, R. H. Lack of effect of beta-2 adrenergic stimulation on human prolactin. Psychoneuroendocrinology 6, 177–179 (1981).

449.        Lerer, B., Birmacher, B., Ebstein, R. P. & Belmaker, R. H. 48-Hour depressive cycling induced by antidepressant. Br. J. Psychiatry 137, 183–185 (1980).

450.        Lerer, B., Ebstein, R. P., Felix, A. & Belmaker, R. H. Lithium amelioration ofreserpine-induced hypoactivity in rats. Int. Pharmacopsychiatry 15, 338–343 (1980).

451.        HERMONI, M., LERER, B., EBSTEIN, R. P. & BELMAKER, R. H. Chronic lithium prevents reserpine‐induced supersensitivity of adenylate cyclase. J. Pharm. Pharmacol. 32, 510–511 (1980).

452.        Lerer, B., Jacobowitz, J. & Wahba, A. Personality features in essential hyperhidrosis. Int. J. Psychiatry Med. 10, 59–67 (1980).

453.        Lerer, B. Odyssey into the unknown. A resident’s views on psychotherapy and supervision. Isr. Ann. Psychiatr. Relat. Discip. 17, 74–80 (1979).

454.        Segal, M., Edelstein, E. L. & Lerer, B. Interaction between delta-6-tetrahydrocannabinol (delta-6-THC) and lithium at the blood brain barrier in rats. Experientia 34, 629 (1978).

455.        Lerer, B. Hyperhidrosis: A review of its psychological aspects. Psychosomatics 18, 28–31 (1977).

456.        Lerer, B., Avni, J. & Wiesel, D. Bad tidings and the hospitalized patient. Ment. Health Soc. 3, 205–211 (1976).

457.        Lerer, B. & Avni, J. Suicide in a general hospital psychiatric department. Psychiatr. Clin. (Basel). 9, 106–111 (1976).